NCT02200380 - A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

April 13, 2016

Conditions

For DonorsRelated Donors Giving Peripheral Blood Stem Cells (PBSC) to a SiblingFor RecipientsAcute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndrome (MDS)Chronic Myelogenous Leukemia (CML)Non-Hodgkins Lymphoma (NHL)Hodgkins Disease (HD)Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

CDX-301

Related donors will receive CDX-301 for 5 days or 7 days.

DRUG

CDX-301 and plerixafor

Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.

Trial Locations (8)

22908

University of Virginia Medical Center, Charlottesville

23298

Virginia Commonwealth University Medical Center, Richmond

27157

Wake Forest Baptist Health, Winston-Salem

30322

Emory University-Winship Cancer Institute, Atlanta

43210

Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus

46237

Indiana Blood and Marrow Transplant, Indianapolis

52242

University of Iowa, Iowa City

90095

UCLA Medical Center, Los Angeles